VURJOR Trademark

Trademark Overview


On Friday, June 2, 2023, a trademark application was filed for VURJOR with the United States Patent and Trademark Office. The USPTO has given the VURJOR trademark a serial number of 79373149. The federal status of this trademark filing is REGISTERED as of Tuesday, March 5, 2024. This trademark is owned by NOVARTIS AG. The VURJOR trademark is filed in the Pharmaceutical Products category with the following description:

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the p...
vurjor

General Information


Serial Number79373149
Word MarkVURJOR
Filing DateFriday, June 2, 2023
Status700 - REGISTERED
Status DateTuesday, March 5, 2024
Registration Number7318555
Registration DateTuesday, March 5, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 19, 2023

Trademark Statements


Goods and ServicesAnti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, July 12, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNOVARTIS AG
Party Type30 - Original Registrant
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Party NameNOVARTIS AG
Party Type20 - Owner at Publication
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Party NameNOVARTIS AG
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Trademark Events


Event DateEvent Description
Tuesday, July 18, 2023APPLICATION FILING RECEIPT MAILED
Thursday, June 29, 2023SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Tuesday, July 11, 2023LIMITATION FROM ORIGINAL APPLICATION ENTERED
Wednesday, July 12, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 18, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, July 18, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, July 18, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, July 18, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, July 18, 2023TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Tuesday, July 18, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 8, 2023ASSIGNED TO EXAMINER
Wednesday, November 29, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, November 14, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 19, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, November 29, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, November 29, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Tuesday, December 19, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 2, 2024NOTIFICATION PROCESSED BY IB
Tuesday, March 5, 2024REGISTERED-PRINCIPAL REGISTER
Thursday, April 4, 2024GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Tuesday, March 5, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Monday, May 6, 2024NOTIFICATION PROCESSED BY IB
Monday, April 8, 2024FINAL DISPOSITION NOTICE SENT TO IB
Monday, April 8, 2024FINAL DISPOSITION PROCESSED